http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이병완,이용호,박철영,이은정,이원영,김난희,최경묵,박근규,최연경,차봉수,이대호,The Korean Diabetes Association (KDA) Fatty Liver Research Group 대한당뇨병학회 2020 Diabetes and Metabolism Journal Vol.44 No.3
This clinical practice position statement, a product of the Fatty Liver Research Group of the Korean Diabetes Association, proposes recommendations for the diagnosis, progression and/or severity assessment, management, and follow-up of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Patients with both T2DM and NAFLD have an increased risk of non-alcoholic steatohepatitis (NASH) and fibrosis and a higher risk of cardiovascular diseases and diabetic complications compared to those without NAFLD. With regards to the evaluation of patients with T2DM and NAFLD, ultrasonography-based stepwise approaches using noninvasive biomarker models such as fibrosis-4 or the NAFLD fibrosis score as well as imaging studies such as vibration-controlled transient elastography with controlled attenuation parameter or magnetic resonance imagingproton density fat fraction are recommended. After the diagnosis of NAFLD, the stage of fibrosis needs to be assessed appropriately. For management, weight reduction achieved by lifestyle modification has proven beneficial and is recommended in combination with antidiabetic agent(s). Evidence that some antidiabetic agents improve NAFLD/NASH with fibrosis in patients with T2DM is emerging. However, there are currently no definite pharmacologic treatments for NAFLD in patients with T2DM. For specific cases, bariatric surgery may be an option if indicated.
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC 대한영상의학회 2019 Korean Journal of Radiology Vol.20 No.7
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection is high in middle-aged and elderly patients. These practice guidelines will provide useful and constructive advice for the clinical management of patients with HCC. A total of 44 experts in hepatology, oncology, surgery, radiology, and radiation oncology in the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2014 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions.
Korean Liver Cancer Study Group,National Cancer Center, Korea 대한영상의학회 2015 Korean Journal of Radiology Vol.16 No.3
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and revised in 2009 by the Korean Liver Cancer Study Group and the National Cancer Center, Korea. Since then, many studies on HCC have been carried out in Korea and other countries. In particular, a substantial body of knowledge has been accumulated on diagnosis, staging, and treatment specific to Asian characteristics, especially Koreans, prompting the proposal of new strategies. Accordingly, the new guideline presented herein was developed on the basis of recent evidence and expert opinions. The primary targets of this guideline are patients with suspicious or newly diagnosed HCC. This guideline provides recommendations for the initial treatment of patients with newly diagnosed HCC.
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Liver Cancer Association (KLCA),National Cancer Center (NCC) Korea 대한영상의학회 2022 Korean Journal of Radiology Vol.23 No.12
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association- National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA),National Cancer Center (NCC) Korea 대한간학회 2022 Clinical and Molecular Hepatology(대한간학회지) Vol.28 No.4
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA),National Cancer Center (NCC) Korea 대한간암학회 2023 대한간암학회지 Vol.23 No.1
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.
Perspective on the management of hepatitis C in the DAA era
( T Jake Liang ),( Liver Diseases Branch ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
The therapy of hepatitis C has experienced a tremendous growth and improvement over the last two decades. The initial monotherapy with interferon α had a dismal result of less than 10% sustained virologic response rate. The combination of interferon α with an old antiviral drug, ribavirin, led to a remarkable increase in the response rate. Next the improved formulation of pegylated interferon resulted in an even higher rate of treatment response. But for many years, the scientific community struggled with the development of new therapeutic regimens to improve on the response rate and to minimize the side effects from interferon based therapy. Basic scientific advances came to the rescue. Based on the knowledge of the viral life cycle and gene functions, a new era of hepatitis C therapy is dawning. With years of discovery work, preclinical testing and finally clinical trials, two direct acting antivirals (DAAs) targeting the protease function of the virus, telaprevir and boceprevir, were approved by the FDA last year. Many other DAAs, closely following behind, would likely be approved in the next few years. The DAAs, in combination with peginterferon and ribavirin, can generate a sustained virologic response rate of more than 60% in HCV genotype 1 patients. The DAAs will likely change the landscape of treatment for hepatitis C. They are associated with more side effects than the standard peginterferon and ribavirin combination, and therefore need careful management. The DAAs also cannot be used alone and should only be used in genotype 1 patients. The DAAs are not approved for liver transplant, HIV/HCV co-infected, hemodialysis or pediatric patients. Deviation from recommended regimens may result in poorer response and potential unanticipated morbidity. Many questions regarding the DAAs remain and need to be adequately addressed, As the armamentarium of DAAs grows for therapy of hepatitis C in the next few years, it will be imperative to develop a rigorous evidence based algorithm and set of recommendations for the use of these drugs.
Perspective on the management of hepatitis C in the DAA era
( T Jake Liang ),( Liver Diseases Branch ),( Niddk ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
The therapy of hepatitis C has experienced a tremendous growth and improvement over the last two decades. The initial monotherapy with interferon?α had a dismal result of less than 10% sustained virologic response rate. The combination of interferon?α with an old antiviral drug, ribavirin, led to a remarkable increase in the response rate. Next the improved formulation of pegylated interferon resulted in an even higher rate of treatment response. But for many years, the scientific community struggled with the development of new therapeutic regimens to improve on the response rate and to minimize the side effects from interferon based therapy. Basic scientific advances came to the rescue. Based on the knowledge of the viral life cycle and gene functions, a new era of hepatitis C therapy is dawning. With years of discovery work, preclinical testing and finally clinical trials, two direct acting antivirals (DAAs) targeting the protease function of the virus, telaprevir and boceprevir, were approved by the FDA last year. Many other DAAs, closely following behind, would likely be approved in the next few years. The DAAs, in combination with peginterferon and ribavirin, can generate a sustained virologic response rate of more than 60% in HCV genotype 1 patients. The DAAs will likely change the landscape of treatment for hepatitis C. They are associated with more side effects than the standard peginterferon and ribavirin combination, and therefore need careful management. The DAAs also cannot be used alone and should only be used in genotype 1 patients. The DAAs are not approved for liver transplant, HIV/HCV co-infected, hemodialysis or pediatric patients. Deviation from recommended regimens may result in poorer response and potential unanticipated morbidity. Many questions regarding the DAAs remain and need to be adequately addressed. As the armamentarium of DAAs grows for therapy of hepatitis C in the next few years, it will be imperative to develop a rigorous evidence?based algorithm and set of recommendations for the use of these drugs.